Protagonist Therapeutics Inc
Protagonist Therapeutics Inc (PTGX) Option Chain
As of September 24, 2026, Protagonist Therapeutics Inc is trading at $137.34, a -0.99% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 47.1%. IV Rank is 36%.
Read more
Tracking the PTGX option chain helps you see every strike and expiry on Protagonist Therapeutics Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Protagonist Therapeutics Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of PTGX options activity at a glance. Use our scanner to monitor the PTGX option chain in real time and filter for the PTGX options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For PTGX stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the PTGX option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where PTGX stock options are being actively traded and where they are not.
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications.
The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Protagonist Therapeutics Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen PTGX options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of PTGX stock options — let the full option chain come to you, pre-filtered and ready to trade.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile81.75% Elevated
- Market cap (M$)8,887
- 52 weeks high-14.59%
- 52 weeks low120.66%
- Analyst recommendationStrong Buy
1.07 - Target price$174.57
27.11% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E132.43
- Future P/E—
- EPS (ttm)1.04
- EPS growth next 5 years—
As of September 24, 2026
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 19.26 | 2 | 0 | 3.51 | 12.34 | 13.70 | 18.00 | 125.00 | -9.88 | — | 4.90 | 0.00 | 4.90 | 0 | 26 | 80.74 |
| 29.90 | 7 | 0 | 4.66 | 7.34 | 9.60 | 14.40 | 130.00 | -6.27 | 0.50 | 4.80 | 0.00 | 2.65 | 0 | 20 | 70.10 |
| 42.11 | 36 | 0 | 6.61 | 2.34 | 6.90 | 11.00 | 135.00 | -2.67 | 2.50 | 6.30 | 0.00 | 4.40 | 0 | 11 | 57.89 |
| 54.66 | 12 | 10 | 5.90 | 0.00 | 4.00 | 7.80 | 140.00 | +0.94 | 6.00 | 7.90 | 2.66 | 4.29 | 5 | 3 | 45.34 |
| 66.36 | 36 | 0 | 4.60 | 0.00 | 2.70 | 6.50 | 145.00 | +4.54 | 8.00 | 11.20 | 7.66 | 1.94 | 0 | 3 | 33.64 |
As of September 24, 2026
Scan the full option chain in one place
Browse the full PTGX option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.
Start your 14-day free trial→